Carter-Wallace inks deals for Clark Labs', BioWhittaker's IVD products.
This article was originally published in The Gray Sheet
Executive SummaryCARTER-WALLACE TO CARRY TORCH FOR CLARK LABS under a letter-of-intent agreement giving Carter-Wallace division Wampole Labs exclusive marketing rights to Clark's entire line of diagnostic test products. One of the primary product lines Wampole is seeking rights to through the ongoing negotiations is Clark's TORCH test panel for Toxoplasma gondii, Rubella, Cytomegalovirus, and Herpes simplex I and II.
You may also be interested in...
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.
February and March inspections deferred unless any are deemed mission critical. China director remains behind as staff evacuate.